03:36 PM EST - Valeant Pharmaceuticals International, Inc. : announced first-quarter financial results for 2013. Valeant's total revenues were $1.068 billion, up 25% compared to the first quarter of 2012, and product revenues were $1.039 billion, up 38% versus the year-ago quarter. The Company reported a net loss of $28 million for the first quarter of 2013, or a loss of $0.09 per diluted share. On a Cash EPS basis, adjusted income was $405 million, or $1.30 per diluted share. Valeant Pharmaceuticals International, Inc.
shares T.VRX are trading down $1.24 at $73.04.
